Synthesis and antibacterial evaluation of a novel series of rifabutin-like spirorifamycins

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 5, 2007, Pages 1181-1184

  Kim, In Ho ^a   Combrink, Keith D ^a   Ma, Zhenkun ^a   Chapo, Katrina ^a   Yan, Dalai ^a   Renick, Paul ^a   Morris, Timothy W ^a   Pulse, Mark ^b   Simecka, Jerry W ^b   Ding, Charles Z ^a  

^a Cumbre Pharmaceuticals Inc   (United States)

^b UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

Ansamycin; Antibacterial; Rifabutin; Rifampin resistant; Rifamycin; RNA polyerase inhibitors; Spirorifamycin; Staphylococcus aureus; Synthesis

Indexed keywords

RIFABUTIN; RIFAMYCIN DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DRUG ACTIVITY; DRUG EFFICACY; DRUG SYNTHESIS; IN VITRO SELECTION; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; SEPTICEMIA; STAPHYLOCOCCUS AUREUS;

ANIMALS; ANTI-BACTERIAL AGENTS; DRUG ADMINISTRATION ROUTES; MICE; MICROBIAL SENSITIVITY TESTS; RIFABUTIN; RIFAMYCINS; SEPSIS; STAPHYLOCOCCUS AUREUS; STRUCTURE-ACTIVITY RELATIONSHIP;

MURINAE; STAPHYLOCOCCUS AUREUS;

EID: 33846895011     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.12.026     Document Type: Article

References (26)

1. Flosss H.G., and Yu T.-W. Chem. Rev. 105 (2005) 621
2. Brufani M. J. Mol. Biol. 87 (1974) 409
3. American Thoracic Society Document. Am. J. Respir. Crit. Care Med. 2003, 167, 603-662.
4. Zavasky D.-M., and Sande M.A. J. Am. Med. Assoc. 279 (1998) 1575
5. Zimmerli W., Widmer A.F., Blatter M., Frei R., and Ochsner P.E. J. Am. Med. Assoc. 279 (1998) 1537
6. Darouichi R.O. N. Engl. J. Med. 350 (2004) 1422
7. Heldman A.W. Am. J. Med. 101 (1996) 68
8. Wilson W.R., et al. J. Am. Med. Assoc. 274 (1995) 1706
9. Karchmer A.W., Archer G.L., and Dismukes W.E. Rev. Infect. Dis. (1983) S543
10. Zumia A., and Grange J.M. Lancet Infect. Dis. 1 Suppl. 3 (2001) 199
11. Bishai W.R., Graham N.M.H., Harrington S., Page C., Moore-Rice K., Hooper N., and Chaisson R.E. N. Engl. J. Med. 334 (1996) 1573
12. Ma Z. Curr. Med. Chem. 1 (2002) 15
13. Denis A., Agouridas C., Auger J.-M., Benedetti Y., Bonnefoy A., Bretin F., Chantot J.-F., Dussarat A., Fromentin C., D'Ambrieres S.G., Lachaud S., Laurin P., Le Martret O., Loyau V., Tessot N., Pejac J.M., and Perrn S. Bioorg. Med. Chem. Lett. 9 (1999) 3075
14. New rifabutin analogs were recently reported to have better in vitro anti-tuberculosis activity than rifabutin and rifampin:. Barluenga J., Aznar F., Garcia A.-B., Cabal M.-P., Palacios J., and Menendez M. Bioorg. Med. Chem. Lett. 16 (2006) 5717
15. Harald G. Chem. Rev. 103 (2003) 2795
16. Che Emmanuel, M. J.; Frye, L. L.; Hickey, E. R.; Liu, W.; Morwick, T. M.; Spreno, D. M.; Sun, S.; Thomson, D. S.; Ward, Y. D.; Young, E. R. WO Patent 0119816, 2001.
17. Pyne S.G. Tetrahedron Lett. 28 (1987) 4737
18. Carboni B., Benalil A., and Vaultier M. J. Org. Chem. 58 (1993) 3736
19. Stahl G.L., Walter R., and Smith C.W. J. Org. Chem. 43 (1978) 2285
20. Akiyama T., Shima H., and Ozaki S. Tetrahedron Lett. 32 (1991) 5593
21. Koh K., Ben R.N., and Durst T. Tetrahedron Lett. 35 (1994) 375
22. Marchi, E.; Montecchi, L. US Patent 4,341,785, 1982.
23. March E., Montecchi L., Venturini A.P., Mascellani G., and Brufani M. J. Med. Chem. 28 (1985) 960
24. Matsuoka M., Makino Y., Takei T., and Kitao T. Chem. Lett. (1980) 743
25. 3) δ 13.73 (s, 1H), 8.14 (s, 1H), 7.31 (br s, 1H), 6.44 (dd, J = 10.8 and 16.0 Hz, 1H), 6.25 (d, J = 10.4 Hz, 1H), 6.10 (dd, J = 16.0 and 6.4 Hz, 1H), 6.01 (dd, J = 12.8 and 0.8 Hz, 1H), 5.09 (dd, J = 6.0 and 12.4 Hz, 1H), 4.97 (d, J = 9.6 Hz, 1H), 3.83 (d, J = 5.6 Hz, 2H), 3.76 (d, J = 10.0 Hz, 2H), 3.56 (br s, 2H), 3.39 (br d, J = 6.0 Hz, 2H), 3.20 (br d, J = 12.0 Hz, 2H), 3.05 (s, 3H), 3.05-3.00 (m, 1H), 2.82 (m, 2H), 2.40-2.34 (m, 1H), 2.25 (s, 3H), 2.07 (s, 3H), 2.06-1.62 (m, 6H), 2.03 (d, J = 3.6 Hz, 6H), 2.02 (s, 3H), 1.71 (s, 3H), 1.03 (d, J = 6.8 Hz, 3H), 1.03-1.02 (m, 1H), 0.85 (d, J = 7.2 Hz, 3H), 0.65 (d, J = 7.2 Hz, 3H), 0.01 (d, J = 7.2 Hz, 3H).
26. 50s were calculated based on three doses with five mice in each dose group.